These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 19228077)

  • 1. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
    Meyer T; Fox R; Ma YT; Ross PJ; James MW; Sturgess R; Stubbs C; Stocken DD; Wall L; Watkinson A; Hacking N; Evans TRJ; Collins P; Hubner RA; Cunningham D; Primrose JN; Johnson PJ; Palmer DH
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):565-575. PubMed ID: 28648803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
    Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
    Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
    Vincenzi B; Santini D; Russo A; Addeo R; Giuliani F; Montella L; Rizzo S; Venditti O; Frezza AM; Caraglia M; Colucci G; Del Prete S; Tonini G
    Oncologist; 2010; 15(1):85-92. PubMed ID: 20051477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
    Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
    Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
    Minami H; Kawada K; Ebi H; Kitagawa K; Kim YI; Araki K; Mukai H; Tahara M; Nakajima H; Nakajima K
    Cancer Sci; 2008 Jul; 99(7):1492-8. PubMed ID: 18477034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
    Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
    Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
    J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
    Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH
    J Clin Oncol; 2010 May; 28(14):2323-30. PubMed ID: 20368568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
    Zhu AX; Rosmorduc O; Evans TR; Ross PJ; Santoro A; Carrilho FJ; Bruix J; Qin S; Thuluvath PJ; Llovet JM; Leberre MA; Jensen M; Meinhardt G; Kang YK
    J Clin Oncol; 2015 Feb; 33(6):559-66. PubMed ID: 25547503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).
    Hubbard JM; Mahoney MR; Loui WS; Roberts LR; Smyrk TC; Gatalica Z; Borad M; Kumar S; Alberts SR
    Target Oncol; 2017 Apr; 12(2):201-209. PubMed ID: 27943153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Baron A; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TRJ; Lopez C; Dutcus C; Guo M; Saito K; Kraljevic S; Tamai T; Ren M; Cheng AL
    Lancet; 2018 Mar; 391(10126):1163-1173. PubMed ID: 29433850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeted therapies in hepatocellular carcinoma.
    Llovet JM; Bruix J
    Hepatology; 2008 Oct; 48(4):1312-27. PubMed ID: 18821591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
    Huang WS; Yang CH
    World J Gastroenterol; 2009 Sep; 15(35):4464-6. PubMed ID: 19764104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
    Nimeiri HS; Oza AM; Morgan RJ; Huo D; Elit L; Knost JA; Wade JL; Agamah E; Vokes EE; Fleming GF
    Gynecol Oncol; 2010 Apr; 117(1):37-40. PubMed ID: 20117828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
    Kelley RK; Nimeiri HS; Munster PN; Vergo MT; Huang Y; Li CM; Hwang J; Mulcahy MF; Yeh BM; Kuhn P; Luttgen MS; Grabowsky JA; Stucky-Marshall L; Korn WM; Ko AH; Bergsland EK; Benson AB; Venook AP
    Ann Oncol; 2013 Jul; 24(7):1900-1907. PubMed ID: 23519998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.
    Dranitsaris G; Vincent MD; Yu J; Huang L; Fang F; Lacouture ME
    Ann Oncol; 2012 Aug; 23(8):2103-2108. PubMed ID: 22228446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
    Zhang Y; Zhang B; Zhang A; Zhao Y; Zhao J; Liu J; Gao J; Fang D; Rao Z
    Clinics (Sao Paulo); 2012 Sep; 67(9):1093-9. PubMed ID: 23018309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Bareford MD; Park MA; Yacoub A; Hamed HA; Tang Y; Cruickshanks N; Eulitt P; Hubbard N; Tye G; Burow ME; Fisher PB; Moran RG; Nephew KP; Grant S; Dent P
    Cancer Res; 2011 Jul; 71(14):4955-67. PubMed ID: 21622715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
    Peer CJ; Sissung TM; Kim A; Jain L; Woo S; Gardner ER; Kirkland CT; Troutman SM; English BC; Richardson ED; Federspiel J; Venzon D; Dahut W; Kohn E; Kummar S; Yarchoan R; Giaccone G; Widemann B; Figg WD
    Clin Cancer Res; 2012 Apr; 18(7):2099-107. PubMed ID: 22307138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.